ABSTRACT Background: Preclinical studies suggest that thymosin α1 has immunoregulatory and anti-inflammatory properties in various septic models. However, whether these effects will transform into improved outcomes in humans with sepsis remains unclear. We performed a meta-analysis to define the role of thymosin α1-based immunomodulatory therapy in sepsis. Methods: We searched Medline and Embase to identify randomized controlled trials that assessed the effect of thymosin α1-based immunomodulatory therapy compared with standard care for adults with sepsis. We calculated risk ratios (RRs) with 95% confidence intervals (CIs) using a random-effects model. The primary outcome was 28-day mortality. Results: Nine articles with 10 trials involving 1425 patients were included. Compared with standard care, thymosin α1-based immunomodulatory therapy was associated with a significant 31% relative risk reduction of 28-day mortality (RR 0.69, 95% CI 0.60-0.80, P<0.001), with no statistical heterogeneity (I 2 =0% ). The benefit was confirmed by trial sequential analysis and was consistent across all subgroup analyses. For secondary outcomes, thymosin α1-based immunomodulatory therapy was associated with shorter length of intensive care unit (ICU) stay and duration of mechanical ventilation, increased T lymphocyte subsets (CD3 + , CD4 + , and CD4 + /CD8 + ), and decreased inflammatory mediators (tumor necrosis factor-α, interleukin-1β, and interleukin-6). Conclusions: Thymosin α1-based immunomodulatory therapy decreases 28-day mortality in patients with sepsis. The benefit might be attributed to its immunomodulatory and anti-inflammatory effects. However, caution should be used to translate these findings to clinical practice, because current evidence is potentially subject to bias. Hence, high-quality and adequately powered trials are still warranted.
S
epsis is a leading cause of death among critically ill patients, which represents a pressing public health crisis and puts an enormous strain on the healthcare system (1) . Despite advances in the diagnosis and treatment, mortality remains strikingly high in patients with sepsis, especially those with septic shock. Since 2002, the Surviving Sepsis Campaign International Guidelines have recommended standard therapeutic bundles for patients with sepsis with a recent update (2) . Clearly, the adoption saves tens of thousands of lives in many conditions. However, it seems that not all septic patients will benefit from the approach, particularly in those with severe infection and multi- ple organ dysfunction. Therefore, new patienttailored therapy strategies are still needed. Until now, the pathophysiology of sepsis has not been fully understood. Recent evidence suggests that a various degree of immunosuppression occurs in sepsis and contributes to the poor outcomes, which brings us a novel understanding of the disorder and a new therapeutic approach (3) . In this context, increasing attention was paid to the immunotherapy. Thymosin α1, a promising immunomodulatory drug, is first described by Goldstein et al. (4) and acts as a regulator of both the innate and adaptive immune system (5) . Preclinical studies yielded encouraging results that thymosin α1 has immunoregulatory and anti-inflammatory properties in various septic models (6, 7) . However, whether these effects will transformation into improved outcomes in humans with sepsis remains unclear. The results of clinical trials regarding thymosin α 1 in sepsis are less persuasive because of the modest sample size and the poor study design. Therefore, we performed a meta-analysis to define the role of thymosin α1-based immunomodulatory therapy in patients with sepsis.
METHODS
We followed the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions to undertake (8) , and the Preferred Reporting Items for Systematic Reviews and MetaAnalyses statement to report this meta-analysis (9).
Registration and Protocol
The meta-analysis has been registered at PROS-PERO and the protocol is available from http:// www.crd.york.ac.uk/PROSPERO/display_record. asp?ID=CRD42016048421 (10) . Registration: PROSPERO CRD42016048421.
Data Sources
We searched Medline and Embase through September 1, 2016 to identify relevant studies, by using both medical subject headings and free text terms, with no language restrictions. Search terms included "thymosin", "sepsis", and "septic". We also manually checked the reference lists of all eligible studies to identify other potentially eligible studies.
Study Selection
Two reviewers (WJG and XPG) initially screened titles and abstracts of identified reports for relevance and then obtained the full text for eligibility. Any discrepancy was resolved by discussion and consultation. Randomized controlled trials (RCTs) evaluating the effect of thymosin α1-based immunomodulatory therapy compared with standard care for adults with sepsis were included.
Data Extraction
Data extraction was performed by two reviewers (WJG and XPG) and confirmed by a third reviewer (ZLM). Extracted data were entered into a standardized Excel (Microsoft Corporation) file. The following information were extracted from each trial: first author, year of publication, number of patients, study population, regimen of thymosin α1-based immunomodulatory therapy (daily dose, duration of treatment, total dose, and combination with ulinastatin or not), and outcome data. When duplicate reports of the same study were found, data from the most complete dataset were extracted for analysis. Discrepancies were resolved by discussion and consultation.
Defined Outcomes
The prespecified primary outcome in the protocol was 28-day mortality. Secondary outcomes included length of intensive care unit (ICU) stay, duration of mechanical ventilation, T lymphocyte subsets (CD3 + , CD4 + , and CD4 + /CD8 + ), and inflammatory mediators (tumor necrosis factor-α, interleukin-1β, and interleukin-6).
Assessment of Risk of Bias
We used the Cochrane collaboration tool to assess the risk of bias of individual study, and with bias domains across studies (11) . All included trials were reviewed and assigned a value of low, unclear, or high to the following domains: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective reporting; and other bias. Trials with high risk of bias for any one or more key domains were considered as at high risk of bias. Trials with low risk of bias for all key domains were considered as at low risk of bias. Otherwise, they were considered as unclear risk of bias.
Quality of Evidence
We used the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach to evaluate the quality of the evidence (12) . GRADE Working Group grades of evidence were as follows: High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. Summary tables were constructed using the GRADE Profiler (version 3.6, GRADEpro).
Statistical Analysis
We calculated relative risks (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes and standardized mean differences (SMDs) with 95% CIs for continuous outcomes. Heterogeneity across studies was quantified using the I 2 statistic; I 2 >50% indicated significant heterogeneity (13) . We pooled outcome data using a random-effects model accounting for clinical heterogeneity. To check the influence of various factors on primary outcome, we further performed post hoc subgroup analyses according to sample size (≥100 vs <100), risk of bias (low vs unclear/high), and immunomodulatory therapy (thymosin α1 alone vs combination with ulinastatin). Only subgroup analyses showing a statistically significant test of interaction (P<0.05) were considered to provide evidence of an intervention effect. Publication bias was assessed by inspection of a funnel plot and Egger's statistic when more than 10 trials were included (14) . Results were considered statistically significant at two-sided P value <0.05. All statistical analyses were performed using Stata 13.0 (StataCorp LP) and RevMan 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark).
Trial Sequential Analysis
In meta-analyses, random errors due to repetitive testing of accumulating data may increase the likelihood of type I error (false positive results). To avoid this, trial sequential monitoring boundaries can be applied to determine whether the evidence in a meta-analysis could be terminated early because the P value was sufficiently small to show the anticipated effect or for futility. This method for meta-analysis that aims to correct for the increased risk of random errors is called trial sequential analysis (TSA), which can determine whether the evidence in a meta-analysis is sufficient and conclusive (15, 16) . When the cumulative Z curve crosses the trial sequential monitoring boundary or enters the futility area, a sufficient level of evidence for the anticipated intervention effect may have been reached and no further trials are needed. If the Z curve does not cross any of the boundaries and the required information size has not been reached, evidence to reach a conclusion is insufficient. We used TSA to calculate diversity adjusted required information size for meta-analysis. Estimating required information size involves a calculation that includes type I error, type II error, the control event proportion, and the effect size. For our TSA, we estimated the required information size using α =0.05 (two-sided), β =0.20 (power 80% ), the control event proportions calculated Records excluded based on titles and abstracts (n = 59)
Full-text articles assessed for eligibility (n = 13)
Full-text articles excluded for duplicate reports (n = 3)
Studies included in qualitative synthesis (n = 10)
Studies included in quantitative synthesis meta-analysis (n = 10)
x, 2017 Volume x Number x from the stand care group, and a relative risk reduction of 10% in 28-day mortality. We used software TSA version 0.9 beta for this analysis. Figure 1 shows the PRISMA statement flowchart, including literature screening, trial selection, and reasons for exclusion. The initial search yielded 115 records. After removing duplicates and screening titles and abstracts, 13 articles were potentially eligible. After checking the full text, nine articles with 10 RCTs were finally included (17) (18) (19) (20) (21) (22) (23) (24) (25) .
RESULTS

Trial Selection
Trial Characteristics
The characteristics of the included trials are presented in Table 1 . These trials are published between 2007 and 2015. The sample size of the trials ranges from 42 to 361, with a total of 1425 patients, 720 in the thymosin α1-based immunomodulatory therapy and 705 in the standard care group. Thymosin α1 is administrated subcutaneously in all trials. Daily dose of thymosin α1 is slightly different. The duration of treatment ranges from 6 to 10 days and the total dose ranges from 9.6 to 22.4mg. Four trials reported thymosin α1 alone (17, (23) (24) (25) , and the remaining six trials reported thymosin α1 combination with ulinastatin (18) (19) (20) (21) (22) (19, 21) , and three reported interleukin-6 (19, 21, 22) .
Risk of Bias Assessment
Details of risk of bias are summarized in Figure  2 . Overall, six trials were categorized as at low risk of bias (17) (18) (19) (20) 24) , and four as at unclear risk of bias (21) (22) (23) 25) . Adequate randomized sequence generated in seven trials (17-20, 24, 25) , and appropriate allocation concealment were reported in six trials (17) (18) (19) (20) 24) . Blinding of outcome assessments was unclear or seldom reported in these trials, but the primary outcome (i.e., 28-day mortality) was less prone to be influenced by lack of blinding.
Original Article Figure  3 ). TSA showed that the cumulative Z curve crossed both the conventional boundary for benefit and the trial sequential monitoring boundary for benefit and entered the area of benefit, which established sufficient evidence, as shown in Figure 4 . Results of subgroup analyses are presented in Table 2 . The results were consistent across all subgroup analyses.
Secondary Outcomes Length of ICU Stay and Duration of Mechanical Ventilation
Thymosin α1-based immunomodulatory therapy was associated with shorter length of ICU stay (SMD -0.50, 95% CI -0.93 to -0.07, P=0.02; Figure 5 ) and duration of mechanical ventilation (SMD -0.70, 95% CI -1.07 to -0.34, P=0.002; Figure 5 ) than standard care.
T Lymphocyte Subsets
Thymosin α1-based immunomodulatory therapy was associated with increased CD3 + (SMD 0.72, 95% CI 0.12 to 1.32, P=0.02; Figure 6 
Inflammatory Mediators
Thymosin α1-based immunomodulatory therapy was associated with decreased tumor necrosis factor-α (SMD -1.21, 95% CI -2.01 to -0.40, P= 0.003; Figure 7 ), interleukin-1β (SMD -1.98, 95% CI -2.47 to -1.49, P<0.001; Figure 7) , and interleukin-6 (SMD -1.09, 95% CI -1.61 to -0.56, P<0.001; Figure 7 ) than standard care.
Publication Bias
For the meta-analysis of 28-day mortality, we detected no evidence of publication bias by assessing funnel plot either visually (Figure 8 ) or statistically (Egger test, P=0.185).
GRADE Quality of Evidence
The GRADE system quality of the evidence for each outcome is shown in Table 3 . The GRADE level of evidence is moderate for 28-day mortality and interleukin-1β, low for length of ICU stay, duration of mechanical ventilation, CD3 + , CD4 + , CD4 + /CD8 + , tumor necrosis factor-α, and interleukin-6.
DISCUSSION
Main Findings
The present meta-analysis comprehensively and systematically reviewed the current available literature to assess the role of thymosin α1-based immunomodulatory therapy in sepsis. The sa- lient findings of this meta-analysis are summarized as follows: 1) compared with standard care, thymosin α1-based immunomodulatory therapy results in a 31% relative risk reduction of 28-day mortality. The benefit is confirmed by TSA and is consistent across all subgroup analyses; 2) thymosin α1-based immunomodulatory therapy further shortens length of ICU stay and duration of mechanical ventilation; and 3) thymosin α1-based immunomodulatory therapy also increases T lymphocyte subsets (CD3 + , CD4 + , and CD4 + /CD8 + ) and decreases inflammatory mediators (tumor necrosis factor-α, interleukin-1β, and interleukin-6). The survival benefit might be attributed to its immunomodulatory and anti-inflammatory effects.
Comparison with Other Meta-Analyses
Two previous meta-analyses on the same topic Original Article have been published (26, 27) . In line with two previous meta-analyses, our meta-analysis also found that thymosin α1-based immunomodulatory therapy decreases 28-day mortality in patients with sepsis. Although the main finding of our meta-analysis was consistent with two previous meta-analyses, the present one generally concurs and further reinforces earlier findings. Differences between the present meta-analysis and the previous ones should be noted. First, our meta-analysis was prospectively registered at PROSPERO and the protocol was available from online website; while both two previous meta-analyses were not registered. The registration may help to improve the transparency, reproducibility, and credibility of our meta-analysis. Second, we further applied TSA to correct for the increased risk of random errors due to repetitive testing of accumulating data in meta-analysis. TSA confirmed our results and suggested sufficient evidence. Third, we also carried out subgroup analyses to test the robustness of our results, which suggested the results were consistent across all subgroup analyses. Last, we used GRADE to evaluate the quality of evidence, which will help healthcare professionals for making clinical decisions.
Implications for Clinical Practice
Given the high mortality and morbidity associated with sepsis, it is essential to delineate the role of thymosin α1-based immunomodulatory therapy in patients with sepsis. Since 2012, the Surviving Sepsis Campaign International Guidelines have suggested not using intravenous immunoglobulins in adult patients with severe sepsis or septic shock (grade 2B) (2), since no sufficient and reliable evidence exists in favor of a benefit. However, so far, the Surviving Sepsis Campaign International Guidelines have not given the recommendation of using thymosin α1-based immunomodulatory therapy in sepsis. The results of our meta-analysis and the previous ones may provide the latest references for updates of the current guidelines.
Strengths and Limitations
Strengths of our meta-analysis include prospective registration, exhaustive literature search including non-English articles, and the compliance with the recommendations of the Cochrane Collaboration and the PRISMA guidelines. In order to increase the robustness of our results, we further applied TSA to assess the impact of random error and repetitive testing and performed subgroup analyses to check the influence of various factors.
Our meta-analysis also have limitations. First, some of the included trials were potentially subject to selection bias. The potential impact on the results would be highlighted and inflated when trials with small sample size were included. However, the main results are confirmed by TSA and are consistent across all subgroup analyses. Second, nearly all included trials were not blinded, which may result in performance and detection bias. But the primary outcome (i.e., 28-day mortality) was less prone to be influenced by lack of blinding. Third, the present meta-analysis was a study-level rather than individual patient data meta-analysis; thus, patient-level confounders are imminent.
CONCLUSIONS
In summary, our meta-analysis suggests that thymosin α1-based immunomodulatory therapy decreases 28-day mortality in patients with sepsis. Despite encouraging results, caution should be used to translate these findings to clinical practice, because current evidence is potentially subject to bias. Hence, we encourage conducting high-quality and adequately powered trials to further confirm the role of thymosin α1-based immunomodulatory therapy before the widespread use of this treatment strategy in patients with sepsis.
